Media headlines about VBI Vaccines (NASDAQ:VBIV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8791529203011 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several brokerages have issued reports on VBIV. Zacks Investment Research downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday, July 15th. ValuEngine raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Noble Financial reissued a “buy” rating on shares of VBI Vaccines in a research report on Monday, May 15th. Finally, TheStreet downgraded shares of VBI Vaccines from a “c-” rating to a “d+” rating in a research report on Wednesday, May 31st. Two research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.38.
Shares of VBI Vaccines (NASDAQ:VBIV) traded down 1.25% on Tuesday, reaching $3.94. 15,787 shares of the company’s stock traded hands. The company has a 50 day moving average of $4.51 and a 200-day moving average of $4.60. VBI Vaccines has a 52 week low of $2.75 and a 52 week high of $6.60. The stock’s market capitalization is $158.50 million.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect VBI Vaccines (NASDAQ:VBIV) Share Price” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/08/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-vbi-vaccines-nasdaqvbiv-share-price.html.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
